Therapeutics
Page 1 to 16 of 76 |     NEXT PAGE >
Spheroids rapidly becoming a preferred 3D culture format By Dr John Comley Spring 2017
There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Read More

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies By Dr Philip Dube Spring 2017
Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation.

Read More

Monitoring the balance between immune repression and stimulation in cancer immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Spring 2017
Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies.

Read More

Fusion Therapy - a new approach to combining treatments By Dr Thomas Mehrling Fall 16
Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand clinical investigation and what is its future potential?

Read More

An Update on Hepatitis B Therapies By Dr John Sullivan-Bolyai Fall 16
The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant burden it places on communities across the globe, hepatitis had been mainly ignored as a health and clinical development priority until recently (1).

Read More

Cell and gene therapies - the emerging fourth pillar of healthcare systems By Keith Thompson Fall 16
As the CEO of an organisation that deals exclusively in cell and gene therapies, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine alongside small molecules, biologics and devices.

Read More

Ex Vivoverus in Vivo - the challenge of generating meaningful results with traditional cell culture By Dr James Lim and Dr Fred Aswad Summer 2016
While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results.

Read More

The Human Micobiome- a new frontier in drug discovery By Lee Jones Summer 2016
There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of human health.

Read More

Synthetic lethality and anti cancer drug discovery By Jonathan D Moore Spring 2016
Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

Read More

The role of immunodeficient animal models in advancing immuno-oncology research By Dr Michael Seiler Spring 2016
From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.

Read More

The Stem Cell Dilemma: reprogramming in-house versus off-the-shelf purchase of commerciallyproduced iPSC-derived cell types. by Dr John Comley Spring 16
The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted.

Read More

CAR-T : Looking beyond the hype. By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann Winter 2015/16
While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify current valuations and investor interest.

Read More

The use of syngeneic models for the discovery of targets for combination therapy and predictive biomarkers of immunotherapy efficacy. By Dr Jean- Pierre Wery Winter 2015/16
Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells.

Read More

Valuation in portfolio management. By Dr Michel Azoulay Winter 2015/16
Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.

Read More

Human ES Cell Derived Functional Cells as Tools in Drug Discovery. Winter 2007 By Dr Petter Björquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner Winter 2007
The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for the pharmaceutical industry.

Read More

Opportunities in Gastroenterology. Winter 2007 By Dirk Reyn Winter 2007
Despite being one of the world’s largest therapeutic areas and presenting huge burdens to healthcare and economies globally, many of the diseases of the gastrointestinal (GI) tract are not well understood and less than optimally treated.

Read More

Therapeutics
Page 1 to 16 of 76 |     NEXT PAGE >